Dermatite atopique: La révolution thérapeutique est en marche

Damsin, Thomas; Libon, Florence; Nikkels, Arjen; Dezfoulian, Bita

Download

Article (Scientific journals)

Dermatite atopique: La révolution thérapeutique est en marche

Damsin, Thomas; Libon, Florence; Nikkels, Arjen et al.

2022 • In Revue Médicale de Liège

Permalink
https://hdl.handle.net/2268/300334

PubMed
35657197

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Dermatite atopique la révolution thérapeutique est en marche.pdf

Author postprint (536.69 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

dermatite atopique; biotherapies; antagonistes IL4 et IL13; inhibiteurs JAK

Abstract :

[fr] Les perspectives thérapeutiques pour les patients atteints de dermatite atopique modérée à sévère ont été complètement bouleversées en 2017 avec l'arrivée sur le marché de la première thérapie ciblée, le dupilumab. Cet anticorps monoclonal dirigé contre les interleukines 4 et 13 permet d'atteindre des scores d'amélioration clinique encore inespérés il y a quelques années. Depuis, d'autres biothérapies comme le tralokinumab ont débarqués sur le marché européen, mais également des petites molécules appelées "inhibiteurs JAK" (upadacitinib, baricitinib, etc.). Cet article présente un état des lieux des options thérapeutiques existantes ou imminentes pour la prise en charge de la dermatite atopique.

Disciplines :

Dermatology

Author, co-author :

Damsin, Thomas ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie

Libon, Florence ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie

Nikkels, Arjen ; Université de Liège - ULiège > Département des sciences cliniques > Dermatologie

Dezfoulian, Bita ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie

Language :

French

Title :

Dermatite atopique: La révolution thérapeutique est en marche

Publication date :

2022

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Available on ORBi :

since 24 February 2023

Statistics

Number of views

157 (13 by ULiège)

Number of downloads

246 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Taïeb A. Atopic dermatitis: definition, epidemiology, natural history, severity and scores. Ann Dermatol Venereol 2005;132:S35-43.
Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018;73:1284-93.
Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc 2017;38:3-8
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016;387:1109-22.
Amar Y, Schneider E, Köberle M, et al. Microbial dysbiosis in a mouse model of atopic dermatitis mimics shifts in human microbiome and correlates with the key pro-inflammatory cytokines IL-4, IL-33 and TSLP. J Eur Acad Dermatol Venereol 2022. doi: 10.1111/jdv.17911.
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018;32:657-82.
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018;32:850-78.
European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186:23-31.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-7.
Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52.
Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021;184:437-49.
Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 2020;145:173-82.
Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020;183:242-55.
Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021;397:2151-68.
Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021;384:1101-12.
Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol 2020;82:1305-13.
Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol 2020;82:823-31.
Pascal C, Maucort-Boulch D, Gilibert S, et al. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. J Eur Acad Dermatol Venereol 2020;34:2339-45.
Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol 2021;157:1047-55.